Riociguat for the Treatment of Pulmonary Arterial Hypertension

Guidelines for the diagnosis and treatment of pulmonary hypertension

Galiè, N., Hoeper, M. M., Humbert, M. J. C., Torbicki, A., Vachiéry, J., Barberà, J. A., Beghetti, M., Corris, P. A., Gaine, S., Gibbs, J. S. R., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp297 · Cited by 3,853

Bosentan Therapy for Pulmonary Arterial Hypertension

Rubin, L. J., Badesch, D. B., Barst, R. J., Galiè, N., Black, C. M., KEOGH, A. M., Pulido, T., Frost, A., Roux, S., Leconte, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012212 · Cited by 2,718

A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension

Barst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. Μ., Tapson, V. F., Bourge, R. C., Brundage, B. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340504 · Cited by 2,688

Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension

Galiè, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D. B., Fleming, T. R., Parpia, T., Burgess, G., Branzi, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050010 · Cited by 2,466

ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension

McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M., Rosenson, R. S., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.01.004 · Cited by 2,359

Inhaled Iloprost for Severe Pulmonary Hypertension

Olschewski, H., Simonneau, G., Galiè, N., HIGENBOTTAM, T. W., Naeije, R., Rubin, L. J., Nikkho, S. M., Speich, R., Hoeper, M. M., Behr, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020204 · Cited by 1,783

Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension

Ghofrani, H. A., D’Armini, A. M., Grimminger, F., Hoeper, M. M., Jansa, P., Kim, N. H., Mayer, E., Simonneau, G., Wilkins, M. R., Fritsch, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209657 · Cited by 1,393

Clinical Correlates and Prognostic Significance of Six-minute Walk Test in Patients with Primary Pulmonary Hypertension: Comparison with Cardiopulmonary Exercise Testing

Miyamoto, S., Nagaya, N., Satoh, T., Kyotani, S., Sakamaki, F., Fujita, M., Nakanishi, N., & Miyatake, K. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.9906015 · Cited by 1,147

An Evaluation of Long-term Survival From Time of Diagnosis in Pulmonary Arterial Hypertension From the REVEAL Registry

Benza, R. L., Miller, D. P., Barst, R. J., Badesch, D. B., Frost, A., & McGoon, M. D. (2012) · CHEST Journal · doi:10.1378/chest.11-1460 · Cited by 1,107

ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension

McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M., Rosenson, R. S., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192230 · Cited by 1,096

Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry

Hoeper, M. M., Sanchez, M.-A. G., Humbert, M. J. C., Pittrow, D., Simonneau, G., Gall, H. J., Grünig, E., Klose, H. F. E., Halank, M., Langleben, D., et al. (2020) · Respiratory Medicine · doi:10.1016/j.rmed.2020.106241 · Cited by 25

Evaluating Haemodynamic Changes: Vericiguat in Patients with Heart Failure with Reduced Ejection Fraction

Suzuki, H., Inoue, T., Terui, Y., Takeuchi, K., Susukita, K., Arai, M., Sato, H., Satoh, T., Yamamoto, S., Yaoita, N., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14802 · Cited by 24

Efficacy and safety of novel-targeted drugs in the treatment of pulmonary arterial hypertension: a Bayesian network meta-analysis

Fu, W., He, W., Li, Y., Chen, Y., Liang, J., Lei, H., Fu, L. N., Chen, Y., Ren, N., Jiang, Q., et al. (2021) · Drug Delivery · doi:10.1080/10717544.2021.1927243 · Cited by 24

Assessment of Clinical Worsening End Points as a Surrogate for Mortality in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Tremblay, É., Gosselin, C., Mai, V., Lajoie, A. C., Kilo, R., Weatherald, J. C., Lacasse, Y., Bonnet, S., Lega, J., & Provencher, S. (2022) · Circulation · doi:10.1161/circulationaha.121.058635 · Cited by 24

Novel use of riociguat in infants with severe pulmonary arterial hypertension unable to wean from inhaled nitric oxide

Domingo, L., Ivy, D. D., Abman, S. H., Grenolds, A., MacLean, J. T., Breaux, J. A., Minford, K. J., & Frank, B. S. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.1014922 · Cited by 24

Soluble Guanylyl Cyclase Activators—Promising Therapeutic Option in the Pharmacotherapy of Heart Failure and Pulmonary Hypertension

Grześk, G., Witczyńska, A., Węglarz, M., Wołowiec, Ł., Nowaczyk, J., Grześk, E., & Nowaczyk, A. (2023) · Molecules · doi:10.3390/molecules28020861 · Cited by 24

Guanylate cyclase stimulators for pulmonary hypertension

Wardle, A. J., Seager, M. J., Wardle, R. A., Tulloh, R. M. R., & Gibbs, J. S. R. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011205.pub2 · Cited by 24

A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension

Sanges, S., Launay, D., Rhee, R. L., Sitbon, O., HACHULLA, E., Mouthon, L., Guillevin, L., Rottat, L., Montani, D., de Groote, P., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207336 · Cited by 24

Structures of soluble guanylate cyclase: implications for regulatory mechanisms and drug development

Gileadi, O. (2014) · Biochemical Society Transactions · doi:10.1042/bst20130228 · Cited by 25

Identifying “super responders” in pulmonary arterial hypertension

Halliday, S. J., & Hemnes, A. R. (2017) · Pulmonary Circulation · doi:10.1177/2045893217697708 · Cited by 24

Evaluation and management approaches for scleroderma lung disease

Schoenfeld, S. R., & Castelino, F. V. (2017) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465817713680 · Cited by 26

Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH

Gall, H. J., Vachiéry, J., Tanabe, N., Halank, M., Orozco‐Levi, M., Mielniczuk, L. M., Chang, M., Vogtländer, K., & Grünig, E. (2018) · Lung · doi:10.1007/s00408-018-0100-3 · Cited by 24

The impact of drug–drug interactions on pulmonary arterial hypertension therapy

Ciracì, R., Tirone, G., & Scaglione, F. (2014) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2014.01.004 · Cited by 24

The Changing Landscape of Pulmonary Arterial Hypertension in the Adult with Congenital Heart Disease

van Dissel, A. C., Mulder, B. J. M., & Bouma, B. J. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6040040 · Cited by 24

New pharmacotherapy options for pulmonary arterial hypertension

Perrin, S., Chaumais, M., O’Connell, C., Amar, D., Savale, L., Jaïs, X., Montani, D., Humbert, M. J. C., Simonneau, G., & Sitbon, O. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1074177 · Cited by 23

Prognosis and response to first-line single and combination therapy in pulmonary arterial hypertension

Kylhammar, D., Persson, L., Hesselstrand, R., & Rådegran, G. (2014) · Scandinavian Cardiovascular Journal · doi:10.3109/14017431.2014.931595 · Cited by 23

Update in treatment options in pulmonary hypertension

Kanwar, M. K., Thenappan, T., & Vachiéry, J. (2016) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2016.01.020 · Cited by 23

Pulmonary arterial hypertension: the case for a bioelectronic treatment

Ntiloudi, D., Qanud, K., Tomaio, J. N., Giannakoulas, G. A., Al‐Abed, Y., & Zanos, S. P. (2019) · Bioelectronic Medicine · doi:10.1186/s42234-019-0036-9 · Cited by 23

Early diagnosis and targeted approaches to pulmonary vascular disease in bronchopulmonary dysplasia

Hocq, C., Vanhoutte, L., Guilloteau, A., Massolo, A. C., Grambezen, B. V., Carkeek, K., Piersigilli, F., & Danhaive, O. (2021) · Pediatric Research · doi:10.1038/s41390-021-01413-w · Cited by 23

Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC

Becker‐Pelster, E., Hahn, M. G., Delbeck, M., Dietz, L., Hüser, J., Kopf, J., Kræmer, T., Marquardt, T., Mondritzki, T., Nagelschmitz, J., et al. (2022) · Respiratory Research · doi:10.1186/s12931-022-02189-1 · Cited by 23

A new day has come: Sotatercept for the treatment of pulmonary arterial hypertension

CASCINO, T. M., Sahay, S., Moles, V., & McLaughlin, V. V. (2024) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2024.09.021 · Cited by 23

Sildenafil for the treatment of pulmonary hypertension in children

Beghetti, M., Wacker, J., & Merali, S. (2014) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.958077 · Cited by 23

Stimulators of the soluble guanylyl cyclase: promising functional insights from rare coding atherosclerosis-related GUCY1A3 variants

Wobst, J., von Ameln, S., Wolf, B. A., Wierer, M., Dang, T. A., Sager, H. B., Tennstedt, S., Hengstenberg, C., Koesling, D., Friebe, A., et al. (2016) · Basic Research in Cardiology · doi:10.1007/s00395-016-0570-5 · Cited by 23

Recent advances in the management of pulmonary arterial hypertension

Tsai, H., Sung, Y. K., & Pérez, V. D. J. (2016) · F1000Research · doi:10.12688/f1000research.9739.1 · Cited by 23

Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension

Khouri, C., Lepelley, M., Roustit, M., Montastruc, F., Humbert, M. J. C., & Cracowski, J. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.12.008 · Cited by 23

Effects of Pulmonary Hypertension and Right Ventricular Function in Short and Long-Term Kidney Function

Naranjo, M., Lo, K. B., Mezue, K. N., & Rangaswami, J. (2018) · Current Cardiology Reviews · doi:10.2174/1573403x14666181008154215 · Cited by 23

Circulating Blood-Based Biomarkers in Pulmonary Hypertension

Banaszkiewicz, M., Gąsecka, A., Darocha, S., Florczyk, M., Pietrasik, A., Kędzierski, P., Piłka, M., Torbicki, A., & Kurzyna, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11020383 · Cited by 23

Next-generation therapeutics for diabetic kidney disease

Yi, T. W., Sridhar, V. S., Scott, J., Nardone, M., & Cherney, D. Z. I. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01042-0 · Cited by 24

BMI and Treatment Response in Patients With Pulmonary Arterial Hypertension

McCarthy, B. E., McClelland, R. L., Appleby, D. H., Moutchia, J., Minhas, J., Min, J., Mazurek, J. A., Smith, K. A., Fritz, J. S., Pugliese, S. C., et al. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.02.041 · Cited by 22

Imbalanced prostanoid release mediates cigarette smoke-induced human pulmonary artery cell proliferation

Alqarni, A. A., Brand, O. J., Pasini, A., Alahmari, M. A., Alghamdi, A., & Pang, L. (2022) · Respiratory Research · doi:10.1186/s12931-022-02056-z · Cited by 22

Riociguat in children with pulmonary arterial hypertension: The PATENT–CHILD study

García‐Aguilar, H., Gorenflo, M., Ivy, D. D., Moledina, S., Castaldi, B., Ishida, H., Cześniewicz, P., Kusa, J., Miera, O., Pattathu, J., et al. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12133 · Cited by 22

Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: From Bedside to Bench and Back Again

Bahi, M., Li, C., Wang, G. C., & Korman, B. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094728 · Cited by 22

Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat in Healthy Young Chinese Male Non-Smokers and Smokers: Results of a Randomized, Double-Blind, Placebo-Controlled Study

Zhao, X., Wang, Z., Wang, Y., Zhang, H., Blode, H., Yoshikawa, K., Becker, C., Unger, S., Frey, R., & Cui, Y. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0337-4 · Cited by 22

Pediatric Cardiac Intensive Care Society 2014 Consensus Statement

Kim, J. S., McSweeney, J. E., Lee, J., & Ivy, D. D. (2016) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000000622 · Cited by 22

Evaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction

Mascherbauer, J., Grünig, E., Halank, M., Hohenforst‐Schmidt, W., Kammerlander, A. A., Pretsch, I., Steringer‐Mascherbauer, R., Ulrich, S., Lang, I. M., Wargenau, M., et al. (2016) · Wiener klinische Wochenschrift · doi:10.1007/s00508-016-1068-8 · Cited by 22

Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1)

Shapiro, S., Torres, F., Feldman, J., KEOGH, A. M., Allard, M., Blair, C. J., Gillies, H., Tislow, J., & Oudiz, R. J. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.03.025 · Cited by 22

The impact of delayed treatment on 6-minute walk distance test in patients with pulmonary arterial hypertension: A meta-analysis

Vizza, C. D., Badagliacca, R., Messick, C. R., Rao, Y., Nelsen, A. C., & Benza, R. L. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.12.016 · Cited by 22

Clinical and hemodynamic benefit of macitentan and riociguat upfront combination in patients with pulmonary arterial hypertension

Sulica, R., Sangli, S. S., Chakravarti, A., & Steiger, D. J. (2019) · Pulmonary Circulation · doi:10.1177/2045894019826944 · Cited by 22

Multiplicity of Nitric Oxide and Natriuretic Peptide Signaling in Heart Failure

Preedy, M. E. J., Baliga, R. S., & Hobbs, A. J. (2019) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000724 · Cited by 22

Pulmonary arterial hypertension populations of special interest: portopulmonary hypertension and pulmonary arterial hypertension associated with congenital heart disease

Savale, L., & Manes, A. (2019) · European Heart Journal Supplements · doi:10.1093/eurheartj/suz221 · Cited by 22

MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study

Humbert, M. J. C., Hassoun, P. M., Chin, K., Bortman, G., Patel, M. J., Rosa, C. L., Fu, W., Loureiro, M. J., & Hoeper, M. M. (2024) · European Respiratory Journal · doi:10.1183/13993003.01110-2024 · Cited by 23

Management of Pulmonary Arterial Hypertension: Current Strategies and Future Prospects

Sharma, M., Paudyal, V., Syed, S., Thapa, R., Kassam, N., & Surani, S. (2025) · Life · doi:10.3390/life15030430 · Cited by 21

Pulmonary Arterial Hypertension: A Current Review of Pharmacological Management

Sahni, S., Ojrzanowski, M., Majewski, S., & Talwar, A. (2015) · Advances in respiratory medicine · doi:10.5603/piap.a2015.0084 · Cited by 21

Associations Between the Cyclic Guanosine Monophosphate Pathway and Cardiovascular Risk Factors: MESA

Ying, W., Zhao, D., Ouyang, P., Subramanya, V., Vaidya, D. M., Ndumele, C. E., Güallar, E., Sharma, K., Shah, S. J., Kass, D. A., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.013149 · Cited by 21

Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension

Momoi, M., Hiraide, T., Shinya, Y., Momota, H., Fukui, S., Kawakami, M., Itabashi, Y., Fukuda, K., & Kataoka, M. (2021) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466621995048 · Cited by 21

Drug Treatment of Heart Failure with Reduced Ejection Fraction: Defining the Role of Vericiguat

Coats, A. J. S., & Tolppanen, H. (2021) · Drugs · doi:10.1007/s40265-021-01586-y · Cited by 21

Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

Benza, R. L., Langleben, D., Hemnes, A. R., Noordegraaf, A. V., Rosenkranz, S., Thenappan, T., Hassoun, P. M., Preston, I. R., Ghio, S., Badagliacca, R., et al. (2022) · European Respiratory Review · doi:10.1183/16000617.0061-2022 · Cited by 21

Use of outcome measures in pulmonary hypertension clinical trials

Parikh, K. S., Rajagopal, S., Arges, K., Ahmad, T., Sivak, J. A., Kaul, P., Shah, S. H., Tapson, V. F., Velazquez, E. J., Douglas, P. S., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.06.010 · Cited by 21

Pharmacokinetic interaction profile of riociguat, a new soluble guanylate cyclase stimulator, in vitro

Rickert-Zacharias, V., Haefeli, W. E., & Weiß, J. (2014) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2014.02.004 · Cited by 22

Treating pulmonary hypertension in pediatrics

Lador, F., Sekarski, N., & Beghetti, M. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1013937 · Cited by 21

Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors

Hoeper, M. M., Klinger, J. R., Benza, R. L., Simonneau, G., Langleben, D., Naeije, R., & Corris, P. A. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.11.001 · Cited by 21

The safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension

Gessler, T., Ghofrani, H. A., Held, M., Klose, H. F. E., Leuchte, H. H., Olschewski, H., Rosenkranz, S., Fels, L. M., Li, N., Ren, D., et al. (2017) · Pulmonary Circulation · doi:10.1177/2045893217706691 · Cited by 21

Changes in hemodynamic classification over time are common in systemic sclerosis‐associated pulmonary hypertension: insights from the PHAROS cohort

Lammi, M. R., Saketkoo, L. A., Gordon, J., & Steen, V. D. (2018) · Pulmonary Circulation · doi:10.1177/2045893218757404 · Cited by 21

Impact of the initiation of balloon pulmonary angioplasty program on referral of patients with chronic thromboembolic pulmonary hypertension to surgery

Amsallem, M., Guihaire, J., Ataam, J. A., Lamrani, L., Boulate, D., Mussot, S., Fabre, D., Taniguchi, Y., Haddad, F., Sitbon, O., et al. (2018) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2018.05.004 · Cited by 21

Riociguat prevents hyperoxia-induced lung injury and pulmonary hypertension in neonatal rats without effects on long bone growth

Donda, K., Zambrano, R. A. P., Moon, Y., Percival, J. M., Vaidya, R., Dapaah-Siakwan, F. M., Luo, S., Duncan, M. R., Bao, Y. L., Wang, L., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0199927 · Cited by 21

Longterm Efficacy and Safety of Monotherapy versus Combination Therapy in Systemic Sclerosis–associated Pulmonary Arterial Hypertension: A Retrospective RESCLE Registry Study

Fernández, M. P., Rubio‐Rivas, M., Tolosa-Vilella, C., del Castillo, A. G., Freire, M., Vargas‐Hitos, J. A., Vargas‐Hitos, J. A., Rodríguez‐Carballeira, M., Ballvé, A. M., Espinosa, G., et al. (2019) · The Journal of Rheumatology · doi:10.3899/jrheum.180595 · Cited by 21

Oxidation of PKGIα mediates an endogenous adaptation to pulmonary hypertension

Rudyk, O., Rowan, A., Prysyazhna, O. D., Krasemann, S., Hartmann, K., Zhang, M., Shah, A. M., Ruppert, C., Weiß, A., SCHERMULY, R. T., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1904064116 · Cited by 21

cGMP Signaling in Cardiovascular Diseases: Linking Genotype and Phenotype

Dang, T. A., Schunkert, H., & Kessler, T. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000744 · Cited by 22

A Review of Clinical Trial Endpoints of Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension and How They Relate to Patient Outcomes in the United States

Divers, C., Platt, D. M., Wang, E., Lin, J., Lingohr-Smith, M., & Mathai, S. C. (2016) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2017.23.1.92 · Cited by 21

Simultaneous quantification of endothelin receptor antagonists and phosphodiesterase 5 inhibitors currently used in pulmonary arterial hypertension

Enderle, Y., Witt, L., Wilkens, H., Grünig, E., Haefeli, W. E., & Burhenne, J. (2017) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.05.052 · Cited by 21

Fundamental and Targeted Approaches in Pulmonary Arterial Hypertension Treatment

Park, J. S., Choi, Y. H., Min, J.-Y., Lee, J., & Shim, G. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17020224 · Cited by 20

An Update on Medical Therapy for Pulmonary Arterial Hypertension

Wu, Y., O’Callaghan, D. S., & Humbert, M. J. C. (2013) · Current Hypertension Reports · doi:10.1007/s11906-013-0394-8 · Cited by 20

Life expectancy after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: a Swedish single‐center study

Kallonen, J., Glaser, N., Bredin, F., Corbascio, M., & Sartipy, U. (2020) · Pulmonary Circulation · doi:10.1177/2045894020918520 · Cited by 21

Interventional and pharmacological management of chronic thromboembolic pulmonary hypertension

Ghofrani, H.-A., D’Armini, A. M., Kim, N. H., Mayer, E., & Simonneau, G. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2020.106293 · Cited by 20

Pulmonary pressure recovery in idiopathic, hereditary and drug and toxin-induced pulmonary arterial hypertension: determinants and clinical impact

Badagliacca, R., Vizza, C. D., Lang, I. M., Sadushi‐Kolici, R., Papa, S., Manzi, G., Filomena, D., Ogawa, A., Shimokawahara, H., & Matsubara, H. (2022) · Vascular Pharmacology · doi:10.1016/j.vph.2022.107099 · Cited by 20

Pulmonary arterial hypertension: Navigating the pathways of progress in diagnosis, treatment, and patient care

Raposo, M. A., Cazeiro, D. I., Guimarães, T., Lousada, N., Freitas, C., Brito, J., Martins, S., Resende, C., Dorfmüller, P., Luís, R., et al. (2024) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2024.03.004 · Cited by 20

Soluble guanylyl cyclase stimulators and activators: Promising drugs for the treatment of hypertension?

Gawryś, O., Kala, P., Sadowski, J., Melenovský, V., Sandner, P., & Červenka, L. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177175 · Cited by 20

Pulmonary Hypertension Associated with Connective Tissue Disease

Mathai, S. C. (2021) · Cardiology Clinics · doi:10.1016/j.ccl.2021.08.003 · Cited by 20

A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension

Wang, S., Yu, M., Zheng, X., & Dong, S. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1523257 · Cited by 20

A focus on riociguat in the treatment of pulmonary arterial hypertension

Toxvig, A. K., Wehland, M., Grimm, D. G., Infanger, M., & Krüger, M. (2019) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13272 · Cited by 20

Dihydroartemisinin Attenuates Pulmonary Hypertension Through Inhibition of Pulmonary Vascular Remodeling in Rats

Tang, M. X., Wang, R., Feng, P., Dong, Q., Chen, W., Zhao, Y., Li, A., Li, H., Chen, J., & Huang, W. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000862 · Cited by 20

Smooth muscle cell CYB5R3 preserves cardiac and vascular function under chronic hypoxic stress

Durgin, B. G., Wood, K. C., Hahn, S. A., McMahon, B., Baust, J., & Straub, A. C. (2021) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2021.09.005 · Cited by 21

Portopulmonary hypertension: An update

Porres‐Aguilar, M., & Mukherjee, D. (2014) · Respirology · doi:10.1111/resp.12455 · Cited by 19

Managing the Patient with Pulmonary Hypertension

Chakinala, M. M., Duncan, M., & Wirth, J. A. (2016) · Cardiology Clinics · doi:10.1016/j.ccl.2016.04.008 · Cited by 19

Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching

Chamorro, V., Morales‐Cano, D., Milara, J., Barreira, B., Moreno, L., Callejo, M., Mondéjar‐Parreño, G., Esquivel‐Ruiz, S., Cortijo, J., Cogolludo, A. L., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191239 · Cited by 19

Cardiac fibrosis: emerging agents in preclinical and clinical development

Spoladore, R., Falasconi, G., Fiore, G., Maio, S. D., Preda, A., Slavich, M., Margonato, A., & Fragasso, G. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1868432 · Cited by 19

Stem cell therapy in pulmonary hypertension: current practice and future opportunities

Zheng, R., Xu, T., Wang, X., Yang, L., Wang, J., & Huang, X. (2023) · European Respiratory Review · doi:10.1183/16000617.0112-2023 · Cited by 19

Health-Related Quality of Life Across the Spectrum of Pulmonary Hypertension

Balasubramanian, A., Larive, A. B., Horn, E. M., DuBrock, H. M., Mehra, R., Jacob, M. S., Hemnes, A. R., Leopold, J. A., Radeva, M., Hill, N. S., et al. (2024) · CHEST Journal · doi:10.1016/j.chest.2024.02.009 · Cited by 19

Pathophysiology and potential treatments of pulmonary hypertension due to systolic left heart failure

Lundgren, J., & Rådegran, G. (2014) · Acta Physiologica · doi:10.1111/apha.12295 · Cited by 19

Quality of life among pulmonary hypertension patients in Finland

Kukkonen, M., Puhakka, A., & Halme, M. K. (2016) · European Clinical Respiratory Journal · doi:10.3402/ecrj.v3.26405 · Cited by 19

Soluble Guanylate Cyclase Stimulators: a Novel Treatment Option for Heart Failure Associated with Cardiorenal Syndromes?

Dubin, R. F., & Shah, S. J. (2016) · Current Heart Failure Reports · doi:10.1007/s11897-016-0290-z · Cited by 20

Extracorporeal membrane oxygenation after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension

Sugiyama, K., Suzuki, S., Fujiyoshi, T., Koizumi, N., Sato, M., & Ogino, H. (2019) · Journal of Cardiac Surgery · doi:10.1111/jocs.14052 · Cited by 19

Pulmonary Arterial Hypertension: A Palliative Medicine Review of the Disease, Its Therapies, and Drug Interactions

Christiansen, D. L., Porter, S., Hurlburt, L., Weiss, A. J., Granton, J. T., & Wentlandt, K. (2019) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2019.11.023 · Cited by 19

Therapeutic Challenges And Advances In The Management Of Systemic Sclerosis-Related Pulmonary Arterial Hypertension (SSc-PAH)

Argula, R. G., Ward, C., & Feghali‐Bostwick, C. A. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s219024 · Cited by 19

Use of medical therapies before pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension patients with severe hemodynamic impairment

Castro, M. A., Piloto, B. M., Fernandes, C. J. C. D. S., Jardim, C., Salibe-Filho, W., Gavilanes, F., Alves, J. L., Morinaga, L. T. K., Hoette, S., Filho, M. T., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0233063 · Cited by 19

The treatment strategy of connective tissue disease associated pulmonary arterial hypertension: Evolving into the future

Zhao, J., Wang, Q., Deng, X., Qian, J., Tian, Z., Liu, Y., Li, M., & Zeng, X. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108192 · Cited by 19

From pathogenesis to therapy – Perspective on treatment strategies in fibrotic diseases

Ramming, A., Dees, C., & Distler, J. H. W. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.06.012 · Cited by 19

An Update on the Management of Pulmonary Arterial Hypertension and the Pharmacist’s Role

Macaulay, T. E., Covell, M. B., & Pogue, K. T. (2015) · Journal of Pharmacy Practice · doi:10.1177/0897190015615902 · Cited by 19

Current Approach to the Diagnosis and Management of Portopulmonary Hypertension

Fussner, L. A., & Krowka, M. J. (2016) · Current Gastroenterology Reports · doi:10.1007/s11894-016-0504-2 · Cited by 19

Riociguat for the Treatment of Raynaud’s Phenomenon: A Single-Dose, Double-Blind, Randomized, Placebo-Controlled Cross-Over Pilot Study (DIGIT)

Huntgeburth, M., Kießling, J., Weimann, G., Wilberg, V., Saleh, S., Hunzelmann, N., & Rosenkranz, S. (2018) · Clinical Drug Investigation · doi:10.1007/s40261-018-0698-1 · Cited by 19

Reducing economic burden and improving quality of life in pulmonary arterial hypertension

Burgoyne, D. S. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88611 · Cited by 18

Soluble guanylyl cyclase: Molecular basis for ligand selectivity and action in vitro and in vivo

Wu, G., Sharina, I. G., & Martin, E. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1007768 · Cited by 20

Medical Management of Pulmonary Arterial Hypertension: Current Approaches and Investigational Drugs

Jin, Q., Chen, D., Zhang, X., Zhang, F., Zhong, D., Lin, D., Guan, L., Pan, W., Zhou, D., & Ge, J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061579 · Cited by 18

Targeting Soluble Guanylyl Cyclase during Ischemia and Reperfusion

Mace, E. H., Kimlinger, M. J., Billings, F. T., & Lopez, M. G. (2023) · Cells · doi:10.3390/cells12141903 · Cited by 18

Oral targeted therapies in the treatment of pulmonary arterial hypertension: A meta-analysis of clinical trials

Zheng, Y., Ma, H., Hu, E., Liu, G., Chen, G., & Xiong, C. (2014) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2014.08.005 · Cited by 18

Building the Case for Novel Clinical Trials in Pulmonary Arterial Hypertension

Ryan, J. J., Rich, J. D., & Maron, B. A. (2015) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.114.001319 · Cited by 18

Idiopathic interstitial pneumonia-associated pulmonary hypertension: A target for therapy?

Nathan, S. D., Behr, J., Cottin, V., Collard, H. R., Hoeper, M. M., Martínez, F. J., & Wells, A. U. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.11.003 · Cited by 18

Cumulative subgroup analysis to reduce waste in clinical research for individualised medicine

Song, F., & Bachmann, M. O. (2016) · BMC Medicine · doi:10.1186/s12916-016-0744-x · Cited by 18

Targeted HFpEF therapy based on matchmaking of human and animal models

Aizpurua, A. B., Schroen, B. L. M., van Bilsen, M., & van Empel, V. P. M. (2018) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00024.2018 · Cited by 20

Chronic thromboembolic pulmonary hypertension (CTEPH): what do we know about it? A comprehensive review of the literature

Albani, S., Biondi, F., Stolfo, D., Giudice, F. L., & Sinagra, G. (2019) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000774 · Cited by 20

Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)

Rubin, L. J., Galiè, N., Grimminger, F., Grünig, E., Humbert, M. J. C., Jing, Z., KEOGH, A. M., Langleben, D., Fritsch, A., Menezes, F., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00090614 · Cited by 221

Riociguat for the Treatment of Pulmonary Hypertension: A Meta-analysis of Randomized Controlled Trials

Alrifai, A., Garnet, B., Shah, V., & Lit, L. (2015) · CHEST Journal · doi:10.1378/chest.2281793

Riociguat in Combination With Endothelin Receptor Antagonists (ERAs) for the Treatment of Pulmonary Arterial Hypertension (PAH): A Subgroup Analysis of PATENT

Hill, N. S., & Sood, N. (2015) · CHEST Journal · doi:10.1378/chest.2281116

September 2013 pulmonary journal club: riociguat; pay the doctor

Robbins, R. (2013) · Southwest Journal of Pulmonary and Critical Care · doi:10.13175/swjpcc116-13

Influence of riociguat treatment on pulmonary arterial hypertension

Zhao, R., & Jiang, Y. (2018) · Herz · doi:10.1007/s00059-018-4697-z · Cited by 8